The pan-Canadian Oncology Drug Review (pCODR) was established by Canada’s provincial and territorial Ministries of Health (with the exception of Quebec) to assess cancer drug therapies and make recommendations to guide drug-funding decisions. The pCODR process brings consistency and clarity to the cancer drug assessment process by looking at clinical evidence, cost-effectiveness and patient perspectives.

pERC Final Recommendation
This pERC Final Recommendation is based on a reconsideration of the Initial Recommendation and feedback from eligible stakeholders. This pERC Final Recommendation supersedes the pERC Initial Recommendation.

Drug:
Regorafenib (Stivarga)

Submitted Funding Request:
Treatment of patients with metastatic colorectal cancer (CRC), and an ECOG status of ≤1, who have been previously treated with fluoropyrimidine-based chemotherapy, oxaliplatin, irinotecan, an anti-VEGF therapy, and, if KRAS wild type, an anti-EGFR therapy

Submitted By: Bayer Inc.  
Manufactured By: Bayer Inc.

NOC Date: March 11, 2013  
Submission Date: December 19, 2014

Initial Recommendation: April 30, 2015  
Final Recommendation: July 16, 2015

pERC RECOMMENDATION
The pCODR Expert Review Committee (pERC) does not recommend funding regorafenib (Stivarga) for patients with metastatic colorectal cancer (mCRC) who have been previously treated with fluoropyrimidine-based chemotherapy, oxaliplatin, irinotecan, an anti-VEGF therapy and, if KRAS wild type an anti-EGFR therapy.

The Committee made this recommendation because, compared with placebo plus best supportive care, regorafenib plus best supportive care had only a very modest progression-free survival and overall survival benefit, moderate but not insignificant toxicities, and a similar decline in quality of life. pERC noted that regorafenib aligned with patient values as there is a need for more effective treatment options. However regorafenib was associated with a similar decline in quality of life to best supportive care and had only a very modest improvement in overall survival.

In addition, the Committee noted that regorafenib could not be considered cost-effective based on the submitter’s submitted and Economic Guidance Panel’s estimates of the range of incremental cost-effectiveness ratios when compared with best supportive care in this population.

POTENTIAL NEXT STEPS FOR STAKEHOLDERS
No next steps were identified.
SUMMARY OF pERC DELIBERATIONS

Metastatic colorectal cancer (mCRC) is the second most commonly diagnosed malignancy in Canada. pERC noted that there are limited effective treatment options for patients with late stage disease who have exhausted all other standard treatment options. pERC noted that patients are currently given best supportive care after being treated with fluoropyrimidine-based chemotherapy, oxaliplatin, irinotecan, an anti-VEGF therapy, and, if their disease is KRAS wild type, an anti-EGFR therapy. For patients whose disease is not KRAS wild type there are fewer treatment options available. The life expectancy of these patients from the time of diagnosis of metastatic disease is approximately two years and is much shorter once all treatment options have been exhausted. pERC agreed that there is a need for additional treatment options that provide a clinically meaningful extension in survival, better symptom control, and maintain or improve quality of life, especially near the end-of-life.

The present review is a resubmission based on new clinical information. pERC deliberated upon two double-blind randomized controlled trials (CORRECT, CONCUR) which compared regorafenib plus best supportive care with placebo plus best supportive care in patients with metastatic colorectal cancer. pERC noted that the original pCODR submission was based on the results of the CORRECT study. Since the original submission, the CONCUR study and an updated analysis from the CORRECT study have been made available. These new data were considered in this resubmission. Both the CORRECT and CONCUR trials used the same study design; however, pERC observed that the patient populations included in the studies differed. In the CORRECT trial, prior to commencing the trial, all of the patients received anti-VEGF therapy (bevacizumab) and 51% had received anti-EGFR therapy (cetuximab or panitumumab). In the CONCUR trial, only about 60% of patients had received prior anti-VEGF or anti-EGFR therapy. In the CORRECT trial, almost 50% of patients in both arms of the study had received ≥4 prior systemic anti-cancer therapies, while in the CONCUR trial, all patients had at least two lines of prior treatment. The time from diagnosis of metastases was ≥18 months for over 80% of all patients in the CORRECT trial and about 60% for all patients in the CONCUR trial. pERC concluded that the patients and the treatment patterns in the CORRECT study were more representative of the Canadian setting compared to the CONCUR study, since virtually all patients in Canada will have received prior anti-VEGF therapy with bevacizumab, would receive more prior lines of systemic therapy for mCRC before considering regorafenib, and are at a later stage of their disease.

pERC observed that the results of the CONCUR trial were consistent with those of the CORRECT trial. pERC also acknowledged that the pCODR Clinical Guidance Panel considered that there was a net clinical benefit with regorafenib. The improvement in median overall survival, the primary outcome, between the regorafenib arm and placebo arm was 1.4 months in the CORRECT trial and 2.5 months in the CONCUR trial. The improvement in median progression free survival was 0.2 months in the CORRECT trial and 1.5 months in the CONCUR trial. All results were statistically significant from both studies; however, the Committee considered these to be very modest improvements in both overall survival and progression free survival. Upon reconsideration of the pERC Initial Recommendation, pERC discussed feedback from the submitter and patient advocacy group regarding the clinical benefit of regorafenib. Both stakeholders indicated that small incremental effects are considered important in this setting where all standard treatment options have been exhausted. Although pERC acknowledged there is a statistically significant improvement in survival with regorafenib, it was not felt that the magnitude of absolute benefit was clinically meaningful. pERC noted that although the relative risk reductions were large, pERC was unable to distinguish which subset of patients benefit more from regorafenib. pERC agreed with feedback from the pCODR Provincial Advisory Group that a future submission of this drug for mCRC would be worth considering if a biomarker analysis identified a sub-population of patients who experience a greater benefit from treatment with regorafenib.

pERC noted that patients’ quality of life declined from baseline to the end of treatment in both the CORRECT and CONCUR studies. These declines were similar in both the regorafenib and placebo arms of the studies. Upon reconsideration of the pERC Initial Recommendation, pERC considered it important to emphasize that regorafenib was not better than placebo in maintaining or improving patients’ quality of life.
life, as measured in the clinical trials. pERC discussed the toxicity profile of regorafenib based on the results of both the CORRECT and CONCUR studies. Adverse events that occurred more frequently in patients treated with regorafenib than placebo included hand-foot skin reaction, fatigue, and diarrhea. pERC noted that these toxicities were likely manageable, but not insignificant, particularly considering that many patients without treatment can feel well and have a good performance status, despite having metastatic disease, and that a high rate of grade 3/4 adverse effects would impair daily functioning. pERC also discussed feedback from the submitter that treatments for late stage mCRC, such as regorafenib, should be considered from the same perspective as other late stage treatments that have been recommended for funding by pERC. Although pERC has recommended drugs for funding with similar efficacy and toxicity results (e.g. survival hazard ratios and discontinuation rates due to adverse events), the Committee considered the value of these factors in its deliberations in the wider context of clinical benefit, including efficacy, safety, burden of illness, other available treatment options and unmet need. It also considered these factors in the context of each specific cancer. Therefore, despite the statistically significant improvement in overall survival and progression-free survival in patients receiving regorafenib compared to placebo, pERC concluded that there was not a net clinical benefit of regorafenib for patients with mCRC due to the very modest magnitude of the survival benefit, the inability of regorafenib to maintain or improve quality of life, and the toxicity profile of the treatment.

pERC deliberated upon patient advocacy group input, which indicated that patients value extending life, maintaining quality of life, and delaying progression. pERC acknowledged there is a need for more options for patients with this disease when all standard treatment options have been exhausted. Upon reconsideration of the pERC Initial Recommendation, pERC acknowledged there were patients who benefited from therapy with regorafenib who did not require early management of treatment-induced toxicities and patients for whom toxicities could be managed well. pERC agreed with the feedback from the patient advocacy group that there are patients for whom regorafenib may be clinically effective while maintaining quality of life; however, pERC was unable to identify this subset of patients based on the clinical trial data or specific bio-markers. pERC again acknowledged the input from patients indicating that as individuals they are willing to tolerate treatment toxicity in return for small benefits. Also, patient input indicated that an oral therapy like regorafenib could improve some aspects of quality of life because patients could receive treatment at home, reducing hospital visits. Therefore upon reconsideration, pERC agreed that regorafenib aligned with patient values. Despite this alignment, pERC maintained that the very modest clinical benefits that were observed with regorafenib were insufficient to recommend funding.

pERC deliberated upon the cost-effectiveness of regorafenib. pERC reviewed the incremental cost-effectiveness estimates provided by both the submitter and the pCODR Economic Guidance Panel (EGP) and noted that regorafenib plus best supportive care was not cost-effective compared with placebo plus best supportive care in either analysis. pERC noted that the EGP estimates were higher than the submitter’s estimates and discussed the assumptions upon which the EGP estimates were based. However, pERC also noted that regorafenib’s lack of cost-effectiveness was not the main reason for the current recommendation.

pERC discussed factors that could impact the feasibility of implementing a positive funding recommendation for regorafenib and noted that regorafenib is expected to be an additional, sequential therapy in the treatment of patients with mCRC. It will not likely replace other therapies and overall treatment costs could be expected to increase if it were funded. Therefore the potential budget impact could be large given the prevalence of mCRC. pERC discussed and agreed with input from the pCODR Provincial Advisory Group regarding the potential for wastage since the tablets are only stable for 28 days after opening the submitter’s bottle and dose modifications/interruptions are likely when using regorafenib.
CONTEXT OF THE RESUBMISSION

A submission for regorafenib (Stivarga) for patients with metastatic colorectal cancer was previously received by pCODR on March 22, 2013 and the pERC Final recommendation was issued on November 15, 2013.

- The pERC Final Recommendation was not to fund regorafenib (Stivarga) in patients with metastatic colorectal cancer who have been previously treated with fluoropyrimidine-based chemotherapy, oxaliplatin, irinotecan, an anti-VEGF therapy, and, if KRAS wild type, an anti-EGFR therapy.
- The resubmission that was made by the submitter provided new information on regorafenib. The new information included:
  - Updated efficacy and safety data from the randomized controlled trial included in the original submission (CORRECT)
  - Clinical data from the ongoing randomized controlled trial CONCUR
  - A revised economic evaluation

EVIDENCE IN BRIEF

pERC deliberated upon:

- a pCODR systematic review
- other literature in the Clinical Guidance Report providing clinical context
- an evaluation of the submitter’s economic model and budget impact analysis
- guidance from pCODR clinical and economic review panels
- input from one patient advocacy group (Colorectal Cancer Association of Canada)
- input from pCODR’s Provincial Advisory Group.

Feedback on the pERC Initial Recommendation was also provided by:

- pCODR’s Provincial Advisory Group
- one patient advocacy group (Colorectal Association of Canada)
- the Submitter (Bayer Inc.)

The pERC Initial recommendation was to not fund regorafenib (Stivarga) for patients with metastatic colorectal cancer (mCRC) who have been previously treated with fluoropyrimidine-based chemotherapy, oxaliplatin, irinotecan, an anti-VEGF therapy and, if KRAS wild type an anti-EGFR therapy.

Feedback on the pERC Initial Recommendation indicated that the submitter and patient advocacy group disagreed, and pCODR’s Provincial Advisory Group agreed with the initial recommendation.

OVERALL CLINICAL BENEFIT

pCODR review scope

The purpose of this review is to evaluate the efficacy and safety of regorafenib (Stivarga) compared to standard care options or placebo in patients with metastatic colorectal cancer (mCRC) who have been previously treated with fluoropyrimidine-based chemotherapy, oxaliplatin, irinotecan, an anti-VEGF therapy and, if their disease is KRAS wild type, an anti-EGFR therapy.

Studies included: Two high quality RCTs

The pCODR systematic review included two phase III, double-blind randomized controlled trials (RCTs), the CORRECT study (multi-national) and CONCUR study (only Asian countries) which evaluated the efficacy and safety of regorafenib versus placebo. Regorafenib was administered at 160 mg once daily for 3 weeks followed by 1 week off treatment. All patients received best supportive care (BSC).

In both the CORRECT and CONCUR studies, the study population included patients with an Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 or 1 and disease progression during or within 3 months following the last administration of approved standard therapies (fluoropyrimidine, oxaliplatin and irinotecan).
Patient populations: ECOG performance status 0-1, prior bevacizumab use in some patients

Patient characteristics appeared to be balanced between the two groups in the CORRECT and CONCUR studies. Patients had a median age of 61 and 58 years in the CORRECT and CONCUR studies, respectively. Patients had an ECOG PS of 0 or 1. pERC noted that patients with ECOG PS of 2 or greater were not included in the study but noted that due to the toxicity profile of regorafenib, treatment with regorafenib would not likely be offered to patients with a poorer performance status. In both studies, all patients had previously been treated with fluoropyrimidine-based chemotherapy, oxaliplatin, and irinotecan.

**CORRECT Study:** All patients had received bevacizumab, an anti-VEGF therapy, and almost 50% of patients in both arms had received ≥4 prior systemic anti-cancer therapies. The time from diagnosis of metastases was ≥18 months for over 80% of all patients. Fifty-four percent and 64% of patients’ mCRC disease had a KRAS mutation in the regorafenib plus BSC and placebo plus BSC groups, respectively.

**CONCUR Study:** Only 24% and 19% of patients treated with regorafenib plus BSC and placebo plus BSC received bevacizumab, respectively. All patients had received at least two prior lines of treatment. The time from diagnosis of metastases was ≥18 months for about 60% of patients. Thirty-four percent and 27% of patients’ mCRC disease had a KRAS mutation in the regorafenib plus BSC and placebo plus BSC groups, respectively.

**Key efficacy results:** Very modest overall survival and progression-free survival benefit

Key efficacy outcomes deliberated on by pERC included overall survival (OS), the primary endpoint of the CORRECT and CONCUR studies, and progression-free survival (PFS).

**CORRECT Study:** pERC noted that at the second interim analysis, the pre-specified conditions for efficacy and for stopping the study were met. The median OS was 6.4 and 5.0 months in the regorafenib plus BSC and placebo plus BSC groups, respectively (HR=0.77, 95% confidence interval (CI) 0.64-0.94). In the updated final analysis, although the value of median OS remained unchanged, there were slightly improved confidence intervals around the HR (HR=0.79, 95%CI 0.66-0.94). The median PFS was 1.9 and 1.7 months in the regorafenib plus BSC and placebo plus BSC groups, respectively (HR=0.49 95%CI 0.42-0.58).

**CONCUR Study:** As noted the median OS was higher in the CONCUR study compared to the CORRECT study. In CONCUR, the median was 8.8 and 6.3 months in the regorafenib plus BSC and placebo plus BSC groups, respectively (HR=0.55, 95%CI 0.40-0.77). Similarly, the median PFS was 3.2 and 1.7 months in the regorafenib plus BSC and placebo plus BSC groups, respectively (HR=0.31, 95%CI 0.22-0.44).

pERC discussed the magnitude of benefit observed in median PFS and OS and acknowledged the pCODR Clinical Guidance Panel had concluded that regorafenib conferred a modest but consistent and statistically significant improvement in OS and that there was a net clinical benefit to the use of regorafenib. However, pERC discussed the magnitude of the benefit in OS and PFS conferred with regorafenib (1.4 and 0.2 months, respectively in the CORRECT study, which was the trial considered to be most relevant to the Canadian population; the OS and PFS were 2.5 and 1.5 months, respectively in the CONCUR study) and considered this benefit to be very modest.

Upon reconsideration of the pERC Initial Recommendation, pERC discussed the feedback received from the submitter and patient advocacy group regarding the clinical benefit of regorafenib. This feedback indicated that small incremental effects are considered important in this setting when all standard treatment options have been exhausted. Although pERC acknowledged that there is a very modest benefit with regorafenib, the Committee felt that the magnitude of absolute benefit was not clinically meaningful. pERC noted that, although the results were statistically significant and the relative risk reductions were large, pERC was unable to distinguish which subset of patients might benefit more from regorafenib and were concerned by the impact of adverse events on quality of life.

**Quality of life:** Decline in quality of life similar to placebo

Health related quality of life (HRQoL) was assessed in the CORRECT and CONCUR studies using EORTC QLQ-C30 and EQ-5D measures. pERC noted that the HRQoL results at the end of treatment had declined to a similar degree in both the regorafenib plus BSC and placebo plus BSC groups when compared with the beginning of treatment. In a post-hoc analysis of the CORRECT study, regorafenib was associated with significantly longer time to deterioration; however, a significant difference was not observed when other end points were applied.
Safety: Dose modifications due to adverse events required
pERC deliberated on the safety data available from the CORRECT and CONCUR studies.

CORRECT Study: Grade 3 treatment-related adverse events (TRAEs) occurred in 51% and 12% of patients in the regorafenib plus BSC and placebo plus BSC groups, respectively. Rates of grade 4 TRAEs were similar between groups. Adverse events that occurred more frequently in patients treated with regorafenib included hand-foot skin reaction, hypertension, and hypophosphatemia. Hepatic failure occurred in 1% of patients. Adverse events leading to dose modifications occurred in 68% and 23% of patients in the regorafenib plus BSC and placebo plus BSC groups, respectively while withdrawals due to adverse events occurred in 19% and 12% of patients treated with regorafenib plus BSC and placebo plus BSC groups, respectively.

CONCUR Study: Adverse events that occurred more frequently in patients treated with regorafenib included hand-foot skin reaction, fatigue, diarrhea, hypertension and rash or skin desquamation. Hepatic failure was not reported as one of the serious adverse events in the study. Adverse events leading to dose modifications occurred in 71% and 16% of patients in the regorafenib plus BSC and placebo plus BSC groups, respectively while withdrawals due to adverse events occurred in 14% and 6% of patients treated with regorafenib plus BSC and placebo plus BSC groups, respectively.

Need: Effective therapies for patients who have exhausted all other treatments
pERC noted that colorectal cancer represents the second most common cause of cancer death in Canadian males and the third most common cause of cancer death in Canadian females. With the availability of cytotoxic chemotherapeutics (fluoropyrimidines, oxaliplatin, irinotecan) and targeted agents (i.e. bevacizumab, cetuximab, panitumumab), median survivals are now estimated to be 20-28 months. Despite these significant improvements, long-term survival is rare, with a 5 year survival rate of less than 10%, and cures are still not anticipated in patients with unresectable, metastatic colorectal cancer. Therefore, there is a need for new effective therapies in this patient population, who are currently treated with best supportive care when treatment options are exhausted. pERC noted that an extra line of therapy is available in the third line setting for patients whose disease is KRAS wild type status, while patients whose mCRC disease has a KRAS mutation have only two lines of available therapy.

PATIENT-BASED VALUES

Values of patients with metastatic colorectal cancer: Need for additional treatments
pERC deliberated upon patient advocacy group input and discussed the values of patients with mCRC. The most frequently reported disease-related symptoms are severe abdominal pain, shortness of breath, cough, fatigue, bloating and loss of appetite; all of which significantly impact a patient’s quality of life. pERC acknowledged that patients indicated that there is a need for an additional therapeutic option in the third or fourth line setting that will help manage their disease and side effects, help maintain quality of life and prolong overall survival.

pERC also acknowledged that there is a considerable caregiver burden with this disease, with the most negative impacts being the management of adverse events, providing emotional support, and dealing with the financial challenges related to disability and the cost of accessing treatment in select provinces that do not currently fund third line therapy.

Upon reconsideration of the pERC Initial Recommendation, pERC discussed feedback regarding the alignment of regorafenib with patient values. pERC again acknowledged the input from patients that as individuals they are willing to tolerate treatment toxicity in return for small benefits. Also, patients considered that an oral therapy like regorafenib could improve some aspects of quality of life because patients could receive treatment at home, reducing the number of hospital visits. However, pERC noted oral and intravenous treatments are not equally funded and this varies by province. Overall, pERC agreed that regorafenib aligned with patient values. Despite this alignment, pERC maintained that the very modest clinical benefits that were observed with regorafenib were insufficient to recommend funding.

Patient values on treatment: Early management of toxicities and disease control
pERC noted that a small number of patients who provided input had experience with regorafenib (n=3). These patients reported awareness of significant adverse events with regorafenib, including hand-foot skin reaction, fatigue, and diarrhea, side effects which patients are well acquainted with from previously
administered therapies. Patients noted that early intervention in the management of these known side effects allowed for better tolerance and longer time on treatment, leading to better disease control in terms of tumour shrinkage/stabilization. pERC noted that fewer clinic/hospital visits can alleviate patients’ stress and regorafenib may provide patients a line of therapy that does not require administration in a cancer treatment facility.

ECONOMIC EVALUATION

Economic model submitted: Cost-utility analysis
The pCODR Economic Guidance Panel assessed an updated cost-utility analysis comparing regorafenib (Stivarga) plus best supportive care (BSC) to placebo plus BSC for patients with metastatic colorectal cancer (mCRC) who had been previously treated with fluoropyrimidine-based chemotherapy, oxaliplatin, irinotecan, an anti-VEGF therapy, and, if their disease was KRAS wild type, an anti-EGFR therapy. The comparison was based on the results of the CORRECT study. The submitted model was a partitioned-survival or area under the curve model.

Basis of the economic model: Clinical and economic inputs
Costs considered in the model provided by the submitter included the cost of treatment, administration, and wastage, and the costs associated with routine follow-up and adverse events.

The key clinical outcomes considered in the model provided by the submitter were overall survival, progression-free survival, and utilities.

Drug costs: Confidential price submitted
At the list price, regorafenib costs $72.62 per 40 mg tablet. At the recommended dose of 160 mg daily for 21 days of a 28-day cycle, the average cost per 28-day course is $6,100.08. At the confidential price provided by the submitter, regorafenib costs $ per 40 mg tablet. At the recommended dose of 160 mg daily for 21 days of a 28-day cycle, the average cost of per 28-day course is $ . (The cost of regorafenib is based on a confidential price submitted by the manufacturer and cannot be disclosed to the public according to the pCODR Disclosure of Information guidelines.)

The submitter’s most recent economic analysis was based on a revised confidential price of regorafenib and addressed concerns in the original submission associated with drug mark-up, co-payments, dispensing fees and accounting for potential wastage as regorafenib is available as a sealed bottle of 28 tablets.

Cost-effectiveness estimates: Not cost-effective at submitted price
The EGP’s reanalyses estimated the extra clinical effect of regorafenib plus BSC to be 0.083 quality adjusted life-years (QALYs). The factors found to have the greatest influence on the incremental effectiveness were the survival benefit of regorafenib plus BSC, the duration of treatment duration, and the time horizon.

pERC reviewed the incremental cost effectiveness estimates provided by both the submitter and the pCODR Economic Guidance Panel (EGP) and determined that regorafenib plus BSC was not cost-effective compared with placebo plus BSC in either analysis. pERC acknowledged that the submitter’s resubmission incorporated feedback on the economic analysis from the original submission for regorafenib. However, pERC noted that the EGP estimates were higher than the submitter’s estimates and discussed the assumptions upon which the EGP estimates were based. pERC agreed with the EGP’s assessment that the submitter’s extrapolation of the data beyond the end of the follow-up period in the clinical trial may have overestimated the overall survival benefit in favor of the regorafenib group. The EGP also considered treatment duration until disease progression and death instead of the duration of treatment from the clinical trial data as the CGP felt that this would more accurately reflect real world practice. pERC noted that these small changes in the estimates of incremental effect and cost had a large impact on the ICER estimates. In conclusion, pERC determined that regorafenib plus BSC is not cost-effective at the submitted price compared with placebo plus BSC.
ADOPTION FEASIBILITY

Considerations for implementation and budget impact: Additional therapy, potential for wastage
pERC discussed the feasibility of implementing a funding recommendation for regorafenib and noted that regorafenib is expected to be an additional, sequential therapy for patients with metastatic colorectal cancer. pERC noted that regorafenib would be a new line of therapy and as a consequence, would result in additional pharmacy dispensing workload and increased monitoring of patients for drug interactions or toxicity management. Regorafenib will not likely replace other therapies and overall treatment costs would therefore increase if it were funded. pERC also noted that in provinces where anti-EGFR therapies (cetuximab and panitumumab) are not currently funded, the budget impact of regorafenib would be larger given the prevalence of mCRC. pERC also noted the Provincial Advisory Group’s concern that drug wastage was likely to occur as tablets are only stable for 28 days after opening the submitter’s original bottle and cannot be repackaged to the correct number of tablets for each treatment cycle. pERC also discussed the feedback from the submitter and patient advocacy group regarding a proposed risk sharing agreement to allow for public funding of regorafenib. pERC noted that it was outside of the Committee’s current mandate to provide advice on this type of implementation issue.
DRUG AND CONDITION INFORMATION

Drug Information
- Multiple kinase inhibitor
- 40 mg film coated tablet
- 160 mg (4 tablets, orally) daily for 3 weeks, followed by 1 week off treatment

Cancer Treated
- Metastatic colorectal cancer
- After treatment with fluoropyrimidine-based chemotherapy, oxaliplatin, irinotecan, an anti-VEGF therapy, and, if their disease is KRAS wild type, an anti-EGFR therapy

Burden of Illness
- Second most common cause of cancer death in Canadian males and the third most common cause of cancer death in Canadian females

Current Standard Treatment
- Best supportive care

Limitations of Current Therapy
- Median survivals for patients with metastatic colorectal cancer are now in the 20-28 month range
- Long-term survival remains rare and cures are still not anticipated in patients with unresectable, metastatic colorectal cancer
- There is an unmet need for those patients who still retain a good performance status despite exhausting all prior standard therapies

ABOUT THIS RECOMMENDATION

The pCODR Expert Review Committee (pERC)
Recommendations are made by the pCODR Expert Review Committee following the pERC Deliberative Framework. pERC members and their roles are as follows:

Dr. Anthony Fields, Oncologist (Chair)  Dr. Bill Evans, Oncologist
Dr. Maureen Trudeau, Oncologist (Vice-Chair)  Dr. Allan Grill, Family Physician
Dr. Scott Berry, Oncologist  Dr. Paul Hoskins, Oncologist
Bryson Brown, Patient Member  Danica Wasney, Pharmacist
Dr. Matthew Cheung, Oncologist  Carole McMahon, Patient Member Alternate
Mario de Lemos, Pharmacist  Jo Nanson, Patient Member
Dr. Sunil Desai, Oncologist  Dr. Tallal Younis, Oncologist
Mike Doyle, Economist  Dr. Kelvin Chan, Oncologist
Dr. Maureen Trudeau chaired the meeting in her capacity as Vice-Chair of pERC. All members participated in deliberations and voting on the initial recommendation except:

- Dr. Kelvin Chan, Dr. Allan Grill, Dr. Paul Hoskins, and Dr. Tallal Younis who were not present for the meeting
- Dr. Anthony Fields who was excluded from chairing and voting due to a conflict of interest
- Dr. Scott Berry who was excluded from voting due to a conflict of interest
- Carole McMahon who did not vote due to her role as a patient member alternate

Dr. Maureen Trudeau chaired the meeting in her capacity as Vice-Chair of pERC. All members participated in deliberations and voting on the final recommendation except:

- Drs. Scott Berry, Mathew Cheung, Kelvin Chan, and Allan Grill who were not present for the meeting
- Dr. Anthony Fields who was excluded from chairing and voting due to a conflict of interest
- Carole McMahon who did not vote due to her role as a patient member alternate

Avoidance of conflicts of interest
All members of the pCODR Expert Review Committee must comply with the pCODR Conflict of Interest Guidelines; individual conflict of interest statements for each member are posted on the pCODR website and pERC members have an obligation to disclose conflicts on an ongoing basis. For the review of Regorafenib (Stivarga) Resubmission for Metastatic Colorectal Cancer, through their declarations, six members had a real, potential or perceived conflict and based on application of the pCODR Conflict of Interest Guidelines, and one of these members was excluded from voting.

Information sources used
The pCODR Expert Review Committee is provided with a pCODR Clinical Guidance Report and a pCODR Economic Guidance Report, which include a summary of patient group and Provincial Advisory Group input, as well as original patient group input submissions to inform their deliberations. pCODR guidance reports are developed following the pCODR review process and are posted on the pCODR website. Please refer to the pCODR guidance reports for more detail on their content.

Consulting publicly disclosed information
pCODR considers it essential that pERC recommendations be based on information that may be publicly disclosed. All information provided to the pCODR Expert Review Committee for its deliberations was handled in accordance with the pCODR Disclosure of Information Guidelines. Bayer Inc., as the primary data owner, did not agree to the disclosure of some economic information, therefore, this information has been redacted in this recommendation and publicly available guidance reports.

Use of this recommendation
This recommendation from the pCODR Expert Review Committee (pERC) is not intended as a substitute for professional advice, but rather to help Canadian health systems leaders and policymakers make well-informed decisions and improve the quality of health care services. While patients and others may use this Recommendation, it is for informational and educational purposes only, and should not be used as a substitute for the application of clinical judgment respecting the care of a particular patient, for professional judgment in any decision-making process, or for professional medical advice.

Disclaimer
pCODR does not assume any legal liability or responsibility for the accuracy, completeness or usefulness of any information, drugs, therapies, treatments, products, processes, or services disclosed. The information is provided “as is” and you are urged to verify it for yourself and consult with medical experts before you rely on it. You shall not hold pCODR responsible for how you use any information provided in this report. This document is composed of interpretation, analysis, and opinion on the basis of information provided by pharmaceutical manufacturers, tumour groups, and other sources. pCODR is not responsible for the use of such interpretation, analysis, and opinion. Pursuant to the foundational documents of pCODR, any findings provided by pCODR are not binding on any organizations, including funding bodies. pCODR hereby disclaims any and all liability for the use of any reports generated by pCODR (for greater certainty, “use” includes but is not limited to a decision by a funding body or other organization to follow or ignore any interpretation, analysis, or opinion provided in a pCODR document).